Navigation Links
July Issue of Journal of Antimicrobial Chemotherapy Highlights,Study of Factive Tablets for Five-Day Treatment of,Community-Acquired Pneumonia

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - Results from the successful clinical trial of Oscient Pharmaceuticals' (Nasdaq: OSCI) FACTIVE(R) (gemifloxacin mesylate) tablets for the five-day treatment of community-acquired pneumonia of mild to moderate severity (CAP) have been published in the July issue of the peer-reviewed Journal of Antimicrobial Chemotherapy, currently available in advance on-line. The data from the Phase III clinical trial comparing a five-day and seven-day course of treatment with FACTIVE for CAP formed the basis of the approval last month from the U.S. Food and Drug Administration (FDA) of FACTIVE for the five-day treatment of CAP. FACTIVE 320 mg once-daily is the only fluoroquinolone antibiotic currently approved in the U.S. for the five-day treatment of both CAP and acute bacterial exacerbations of chronic bronchitis (AECB).

"The Phase III trial of FACTIVE demonstrated the efficacy of five-day FACTIVE to treat community-acquired pneumonia," stated Thomas File, M.D., Professor of Internal Medicine and Head of the Infectious Disease Section, Northeastern Ohio Universities College of Medicine and the lead author of the article. "The publication of these data are adding to the body of scientific evidence that demonstrates the importance of short courses of potent antibiotic therapy in treating community-acquired pneumonia, as recommended in the CAP treatment guidelines from the Infectious Diseases Society of America and the American Thoracic Society."

"Following approval last month, we have been discussing the shortened treatment duration for FACTIVE in CAP with physicians and are planning a larger-scale campaign for this fall, in advance of the respiratory tract infection season," stated Steven M. Rauscher, President and CEO of Oscient Pharmaceuticals. "Conducting a successful Phase III trial showing comparability between the five and seven-day treatment regimens for FACTIVE was
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
2. FDA Issues Safety Alert on Avandia
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
5. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
6. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
7. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
10. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:5/15/2008)... France, May 15 /- Cerenis,Therapeuti...ompany,developing HDL-related compounds for the tr...today announced that it has completed a Phase I,cl...d product candidates.,CER-002 is a peroxisome prol...agonist in development for the treatment of cardio...
(Date:5/15/2008)... CenterWatch, a publishing and,information service...l,trials, finds that investigative sites are requi...) systems. More than 75% of respondents to a recen...trained on three or more,EDC systems. In addition,...eir EDC training had improved., State of the Clin...
(Date:5/15/2008)...wire-FirstCall/ -- Novavax, Inc. (Nasdaq:,NVAX) to...the Phase I/IIa,study of its pandemic influenza va...cts. Favorable interim results from the first phas...70 healthy adult volunteers, were,reported in Dece... vaccine,is well tolerated and immunogenic at the ...
(Date:5/15/2008)... Plan Positions Blue Cross Blue Shield of Mic...rt from HealthLeaders-Inter...ealthLeaders-InterStudy, the,leading provider of m...he,economy continues to stagnate in Michigan, Blue...uipped of all of its competitors to weather the,ec...
Breaking Medicine Technology:Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 3Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 1Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 5Phlo Reports Sharp Revenue Increase 3441 1Phlo Reports Sharp Revenue Increase 3441 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 1Cancer Cure Coalition Proposes Major Changes at the FDA 1404 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 3Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 1Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 2Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 3Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 4
...0, 2007 - Valeant,Pharmaceuticals International (N...2 data for retigabine, a first-in-class,neuronal p...ndependent, scientific journal. The authors conclu...rated reduction in monthly,seizure rates in this s...TORE2) are currently underway to further investiga...
...2007 - The two most,prevalent forms of genetic men... share a common cause, according to researchers at...em, a crippled,communication network in the brain,... genetics of the disorders are very different, the...id Daniel Madison,PhD, associate professor of mol...
Other Medicine Technology:Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 2Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 3Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 2Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 3Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 4
(Date:5/16/2008)...eficiency were more likely to suffer recurrence, d...thDay News) -- Women with breast cancer who have a... more likely to have a recurrence or to die from t...y, the researchers also found that only 24 percent...when they were diagnosed. , "This study found t...
(Date:5/16/2008)... Calif., May 16 /PRNewswire-FirstCall/ -- Anesiva,.... McLaughlin, the company,s,chief executive office...obal Healthcare Conference in New York City on May...ebcast or the subsequent archived recording, log o... page, and click on Events.,Please connect to Anes...
(Date:5/15/2008)..., illness, violence and other problems that can un...to experience temporary separations from one or bo...rgarten. Published in the May/June issue of Ambul... Rochester, New York, warns that such kids are at ...these separations are good predictors of which chi...
(Date:5/15/2008)...5 /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,I...ina Yingxia" or "the,Company"), a leading provider...lopment, manufacture and distribution of organic n...l care products in the People,s Republic,of China ...the first,quarter ended March 31, 2008., First ...
Breaking Medicine News(10 mins):Health News:Low Levels of Vitamin D Spell Trouble for Breast Cancer Patients 2Health News:Low Levels of Vitamin D Spell Trouble for Breast Cancer Patients 3Health News:Separation from mom, dad linked with learning trouble in kids 2Health News:Separation from mom, dad linked with learning trouble in kids 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9
...Daniel Stetson have reported in the Journal Immuni...rent mechanism to viral DNA infection. // Viruses...to DNA and RNA viruses and researchers have found ...ognisation of these viral products in the host is ...
...ngcheng Zhang from Whitehead Institute for Biomedi... of growth factors// which enriches and increases ...it could be injected into the recipient. Stem ce... stem cells required for a therapy is very high an...
...om Motor Neurone Disease (MND), a fatal nerve dise...a simple ventilator and facemask//. Patients suff...it from the new technique called non-invasive vent...e with MND who suffer from weakness of the respira...
...ffective as it is claimed to be. Therefore purchas...t// is viewed as nothing more than a waste of mone... on the above finding, several recommendations hav...treatment of coughs by the American College of Che...
Other Medicine News:
... Novametrix' family of capnography products. Along...handheld, mainstream capnographs available today, ...rway condition and ventilatory status. Based on th...iniaturized the size, not the performance. TIDAL W...
The Models 512 and 513 handheld pulse oximeters incorporate "digital signal processing. This advanced technology is able to process pulsatile signals at much higher resolutions and speeds of 100 time
...ulse Oximeter is a one-of-a-kind oximeter that off...tion of the N-20PA has been shock-tested, vibratio... conditions it has even withstood the rigors of M... check measurements and also useful for continuous...
...er with Oxismart XL Advanced Signal Processing rea...through nonspecific noise to find the pulse and tr... N395 monitor is also equipped with SatSeconds Ala...mable alarm sensitivity for pulse oximetry. SatSec...
Medicine Products: